Literature DB >> 30483954

Analysis of the prognostic relevance of sex-steroid hormonal receptor mRNA expression in muscle-invasive urothelial carcinoma of the urinary bladder.

Philipp Erben1, Danijel Sikic2, Ralph M Wirtz3, Thomas Martini4, Cleo-Aron Weis5, Johannes Breyer6, Wolfgang Otto6, Bastian Keck7, Arndt Hartmann8, Christian Bolenz4.   

Abstract

Muscle-invasive urothelial carcinoma of the urinary bladder (UCB) often recurs following radical cystectomy (RC). An altered expression of sex-steroid hormone receptors has been associated with oncological outcomes of UCB and may represent therapeutic targets. Here the expression of different hormone receptors was measured on mRNA levels in patients treated by RC and associated with outcomes. Androgen receptor (AR), estrogen receptor 1 (ESR1), and progesterone receptor (PGR) mRNA expression was assessed by quantitative reverse transcription polymerase chain reaction (RT-qPCR) in RC samples of 87 patients with a median age of 66 (39-88) years. Univariate and multivariate analyses were performed to test associations with pathological and clinical characteristics as well as recurrence-free (RFS) and disease-specific survival (DSS). AR mRNA expression was lower in comparison with ESR1 and PGR expression (p < 0.0001). In univariate analysis, high expression levels of AR were associated with reduced RFS (HR 2.8, p = 0.015) and DSS (HR 2.8, p = 0.010). High AR mRNA expression and a positive lymph node status were independent predictors for reduced RFS (HR 2.5, p = 0.0049) and DSS (HR 3.4, p = 0.009). In patients with low AR mRNA expression, an increased ESR1 and PGR mRNA expression were associated with reduced RFS and DSS. High expression levels of AR are significantly associated with adverse outcome in patients with muscle-invasive UCB following RC. ESR1 and PGR expression status can further stratify patients with low AR expression into subgroups with significantly reduced RFS and DSS. Therapeutic targeting of AR may influence outcomes in patients with UCB.

Entities:  

Keywords:  Androgen receptor; Bladder cancer; ESR; Estrogen receptor; Progesterone receptor; Urothelial carcinoma

Mesh:

Substances:

Year:  2018        PMID: 30483954     DOI: 10.1007/s00428-018-2496-9

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  6 in total

1.  Reproductive and hormonal factors and bladder cancer risk: a prospective study and meta-analysis.

Authors:  Xin Xu; Qiwang Mo; Haixiang Shen; Song Wang; Ben Liu
Journal:  Aging (Albany NY)       Date:  2020-07-06       Impact factor: 5.682

2.  Neuropilin-2 and Its Transcript Variants Correlate with Clinical Outcome in Bladder Cancer.

Authors:  Sarah Förster; Maryam Givehchi; Katja Nitschke; Thomas Mayr; Kerstin Kilian; Samikshan Dutta; Kaustubh Datta; Philipp Nuhn; Zoran Popovic; Michael H Muders; Philipp Erben
Journal:  Genes (Basel)       Date:  2021-04-09       Impact factor: 4.096

3.  Identification of Prognostic Biomarkers for Bladder Cancer Based on DNA Methylation Profile.

Authors:  Shumei Zhang; Jingyu Zhang; Qichao Zhang; Yingjian Liang; Youwen Du; Guohua Wang
Journal:  Front Cell Dev Biol       Date:  2022-01-31

4.  KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer.

Authors:  Hendrik Jütte; Moritz Reike; Ralph M Wirtz; Maximilian Kriegmair; Philipp Erben; Karl Tully; Veronika Weyerer; Markus Eckstein; Arndt Hartmann; Sebastian Eidt; Felix Wezel; Christian Bolenz; Andrea Tannapfel; Joachim Noldus; Florian Roghmann
Journal:  J Pers Med       Date:  2021-05-26

Review 5.  The Role of Estrogen Receptors in Urothelial Cancer.

Authors:  Takuro Goto; Hiroshi Miyamoto
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-16       Impact factor: 5.555

Review 6.  The prognostic role of steroid hormone receptor signaling pathways in urothelial carcinoma.

Authors:  Yujiro Nagata; Hiroshi Miyamoto
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.